Rheumatoid Arthritis Research Reagents

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting approximately 1% of the global population, characterized by persistent synovial inflammation, pannus formation, and progressive cartilage and bone destruction. Anti-citrullinated protein antibodies (ACPA/anti-CCP) and rheumatoid factor (RF) define seropositive RA, which carries a worse prognosis and higher joint erosion risk. Treatment follows a treat-to-target strategy with conventional DMARDs (methotrexate), biologics — anti-TNF-α (infliximab, adalimumab, etanercept), anti-IL-6R (tocilizumab, sarilumab), CTLA-4-Ig (abatacept), anti-CD20 (rituximab) — and JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Immunogenicity monitoring through anti-drug antibody (ADA) detection is essential for biologic-treated patients with secondary treatment failure.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Rheumatoid Arthritis Research Reagents — key pathogenic pathways including TNF-alpha synovial inflammation, IL-6 trans-signaling, ACPA autoimmunity, and RANKL-driven bone erosion

Fig. 1 Key pathogenic pathways and research targets in rheumatoid arthritis. TNF-α drives synovial inflammation; IL-6 trans-signaling amplifies systemic response; ACPA/anti-CCP targets citrullinated autoantigens; RANKL mediates osteoclast-driven bone erosion. Key research targets highlighted in orange.

abinScience provides validated reference antibodies, anti-drug antibodies, and ADA ELISA kits for all major RA biologics — including complete ADA toolkits for infliximab, adalimumab, tocilizumab, sarilumab, and abatacept. Anti-citrulline and anti-CRP monoclonal antibodies support diagnostic assay development. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

TNF-α — TNF-α is the central pro-inflammatory cytokine in RA, driving synovial inflammation, osteoclast activation, and cartilage degradation. Anti-TNF-α agents (infliximab, adalimumab, etanercept, golimumab, certolizumab) remain the most widely prescribed biologic class. abinScience offers complete ADA toolkits for both infliximab and adalimumab: reference antibodies, drug-level ELISA kits, ADA ELISA kits, and neutralizing antibody ELISA kits, supporting therapeutic drug monitoring (TDM) research and biosimilar development.
→ Browse TNF-α antibodies, proteins & ELISA kits

IL-6 / IL-6R — IL-6 trans-signaling drives systemic inflammation, CRP production, and joint destruction in RA. Anti-IL-6R biologics (tocilizumab, sarilumab) are particularly effective in patients with elevated acute-phase reactants. abinScience offers complete ADA toolkits for both tocilizumab (9 products) and sarilumab (9 products): reference antibodies, neutralizing and non-neutralizing anti-drug antibodies, drug-level ELISA, ADA ELISA, and neutralizing antibody ELISA kits.
→ Browse IL-6 / IL-6R antibodies, proteins & ELISA kits

ACPA / Citrullinated Antigens — Anti-citrullinated protein antibodies (ACPA/anti-CCP) are the most specific serological marker for RA (>95% specificity), often detectable years before clinical onset. Anti-citrullinated collagen type II recombinant antibodies (ACC1, ACC4 clones) and anti-citrulline antibodies support diagnostic ELISA development, epitope mapping, and autoantibody characterization. Anti-CRP monoclonal antibodies (matched-pair clones) are also available for inflammation monitoring assays.
→ Browse citrullinated antigen antibodies

RANKL / OPG — RANKL (TNFSF11) drives osteoclastogenesis and bone erosion in RA by binding RANK on osteoclast precursors. OPG (osteoprotegerin) acts as a decoy receptor to block RANKL signaling. Anti-RANKL reference antibodies (denosumab), anti-denosumab neutralizing antibody ELISA kits, and anti-RANKL polyclonal antibodies support bone remodeling research, joint protection studies, and denosumab immunogenicity monitoring.
→ Browse RANKL antibodies & ELISA kits

References

1. Smolen JS, et al. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. DOI

2. Aletaha D, et al. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-1372. DOI

3. McInnes IB, et al. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337. DOI